Search PubMed⌕ Search

Biomedical subjects

V Ramesh

Publications and source records attributed to V Ramesh.

296 records · Page 17Linked to original sources
PubMedDate not supplied

Leprosy in the Union Territory of Delhi.

One hundred and seventy seven patients of leprosy residing in Delhi comprised 16.4% of the total Urban Leprosy Centre attendance in a three-year retrospective study with a M:F ratio of 3:1. The average age at onset of disease was 28.75% years and childhood leprosy was only 6.78%. The cases of pauci- and multibacillary leprosy were almost evenly distributed. Borderline leprosy (including BT, BB & BL of Ridley-Jopling classification) comprised the largest single group with 51.42%, followed by Lepromatous with 21.47%. In 90% cases the high probability of acquiring infection during period of stay in the city and the involvement of lower age-group are pointers towards the endemic nature of the disease in the region.

Age Factors↗
PubMedDate not supplied

Lymphocytic infiltration of skin of Jessner-Kanof masquerading as borderline leprosy.

A case of pseudolymphoma from India is being reported which had been masquerading for quite some time as a case of borderline leprosy. The patient has been having for the past 16 years, recurrent, occasionally pruritic, multiple, bilateral, erythematous papules and plaques, which on casual examination elsewhere had suggested leprosy.

Diagnosis, Differential↗
PubMedDate not supplied

Efficacy of low fat diet in the treatment of benign breast disease.

BACKGROUND: Previous studies have shown that lipid abnormalities have a role in the pathogenesis of benign breast disease. However, few investigators have tried to reduce dietary fat to treat this disorder. METHODS: Between 1990 and 1993, we conducted a prospective cohort study to find out the efficacy of a low fat diet (less than 15% fat-derived calories) in the treatment of benign breast disease in patients who had been symptomatic for 6 months or more. The study was conducted in two phases. In the first phase 36 patients were alternately assigned to control and treatment groups for 6 months and in the second phase 121 patients (including all those in phase I) were given treatment (median follow up 25 months, range 3 to 39 months). Detailed lipid profiles were studied at the time of presentation and at 4 and 5 months. RESULTS: Phase I results showed that after 6 months none of the patients in the control group had experienced any alteration in their symptoms and signs but in the treatment group 12 out of 17 improved. In phase II improvement in pain (68 out of 97; 70%), nodularity (51 out of 79; 64%) and discharge (15 out of 19; 80%) was seen. There was a significant decline in the mean values of total cholesterol and high-density lipoproteins at the end of 5 months of treatment. CONCLUSION: A low fat diet improves the symptoms as well as the lipid profile in patients with benign breast disease.

Adolescent↗
PubMedDate not supplied

Picrorhiza kurroa (Kutaki) Royle ex Benth as a hepatoprotective agent--experimental & clinical studies.

Picrorhiza kurroa (Pk), a known hepatoprotective plant, was studied in experimental and clinical situtations. The standardization of active principles--Picroside 1 and 2 was done with High Performance Liquid Chromatography. Picroside 1 ranged from 2.72 to 2.88 mg/capsule and picroside 2 from 5.50 to 6.00 mg/capsule. In the galactosamine-induced liver injury in rats, Pk at a dose of 200 mg/kg p.o. showed a significant reduction (p < 0.05) in liver lipid content, GOT and GPT. In a randomised, double-blind placebo controlled trial in patients diagnosed to have acute viral hepatitis (HBsAg negative), Pk root powder 375 mg three times a day was given for 2 weeks (n = 15) or a matching placebo (n = 18) was given. Difference in values of bilirubin, SGOT and SGPT was significant between placebo and Pk groups. The time in days required for total serum bilirubin to drop to average value of 2.5 mg% was 75.9 days in placebo as against 27.44 days in Pk group. The present study has shown a biological plausability of efficacy of Pk as supported by clinical trial in viral hepatitis, hepatoprotection in animal model and an approach for standardizing extracts based on picroside content.

Acute Disease↗